{"url_path":"/sec/grce/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-025662-index.html","accession_number":"0001140361-26-025662","cik":"0001444192","ticker":"GRCE","issuer_name":"Grace Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-025662-index.html","primary_entity_key":"0001444192","primary_entity_name":"Grace Therapeutics, Inc."},"word_count":184,"has_tables":true,"body_markdown":"Item 5.\n\nMarket for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\n\n \n\nMarket Information\n\n \n\nShares of our common stock are traded on the Nasdaq Capital Market under the symbol “GRCE.”\n\n \n\nHolders\n\n \n\nAs of June 15, 2026, there were 27 holders of record of our common stock. The actual number of our stockholders is greater than this number of record holders because most of our stockholders are beneficial owners whose shares are held in street name by brokers and other nominees.\n\n \n\nDividends\n\n \n\nWe do not anticipate paying any cash dividend on our common stock in the foreseeable future. We presently intend to retain any future earnings to finance the expansion and growth of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors the board of directors deems relevant. In addition, the terms of any future debt or credit facility may preclude us from paying dividends.\n\n \n\nRecent Sales of Unregistered Securities\n\n \n\nNone.\n\n \n\nIssuer Repurchases of Equity Securities\n\n \n\nNone."}